RPG Investment Advisory LLC Purchases 3,410 Shares of Johnson & Johnson $JNJ

Key Points

• RPG Investment Advisory LLC increased its stake in Johnson & Johnson by 77.3%, owning 7,820 shares valued at approximately $1.3 million as of the latest SEC filing.
• Johnson & Johnson reported earnings per share of $2.77 for the last quarter, surpassing estimates and reflecting a 5.8% increase in revenue year-over-year.
• The company announced a quarterly dividend of $1.30 per share, resulting in an annualized yield of 2.9%, with an upcoming ex-dividend date on August 26.

RPG Investment Advisory LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 77.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,820 shares of the company's stock after acquiring an additional 3,410 shares during the quarter. RPG Investment Advisory LLC's holdings in Johnson & Johnson were worth $1,297,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of JNJ. Highline Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at about $47,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at about $49,000. Capital A Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at about $50,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.1%

Johnson & Johnson stock traded up $0.1680 during trading hours on Friday, reaching $179.0980. The company had a trading volume of 9,523,149 shares, compared to its average volume of 8,494,048. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a 50-day moving average price of $163.48 and a 200 day moving average price of $159.26. The firm has a market cap of $431.33 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 2.28 and a beta of 0.41. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the firm earned $2.82 EPS. The business's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's payout ratio is 55.61%.

Analyst Ratings Changes

JNJ has been the topic of a number of research reports. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Guggenheim reissued a "neutral" rating and set a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Finally, Royal Bank Of Canada lifted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.